NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.90 -0.67 (-0.86%) GOLD FUTURES
2,336.80 -56.10 (-2.34%) DOW
39,062.52 -608.52 (-1.53%) Bitcoin GBP
52,987.88 -1,875.46 (-3.42%)
BioMarin Pharmaceutical Inc. (BM8.F)
| Previous close | 71.04 |
| Open | 70.74 |
| Bid | 70.02 x 2300 |
| Ask | 70.14 x 2200 |
| Day's range | 70.74 - 70.74 |
| 52-week range | 70.00 - 90.52 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 13.432B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 72.93 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada.
- PR Newswire
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society (PES) Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine'
- PR Newswire
BioMarin Reports Record Financial Results for the First Quarter 2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the quarter ended March 31, 2024.
